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L-Lactate protects neurons against 
excitotoxicity: implication of an 
ATP-mediated signaling cascade
P. Jourdain1,3, I. Allaman1, K. Rothenfusser3, H. Fiumelli2, P. Marquet3 & P. J. Magistretti1,2,3
Converging experimental data indicate a neuroprotective action of L-Lactate. Using Digital 
Holographic Microscopy, we observe that transient application of glutamate (100 μM; 2 min) elicits a 
NMDA-dependent death in 65% of mouse cortical neurons in culture. In the presence of L-Lactate (or 
Pyruvate), the percentage of neuronal death decreases to 32%. UK5099, a blocker of the Mitochondrial 
Pyruvate Carrier, fully prevents L-Lactate-mediated neuroprotection. In addition, L-Lactate-induced 
neuroprotection is not only inhibited by probenicid and carbenoxolone, two blockers of ATP channel 
pannexins, but also abolished by apyrase, an enzyme degrading ATP, suggesting that ATP produced 
by the Lactate/Pyruvate pathway is released to act on purinergic receptors in an autocrine/paracrine 
manner. Finally, pharmacological approaches support the involvement of the P2Y receptors associated 
to the PI3-kinase pathway, leading to activation of KATP channels. This set of results indicates that 
L-Lactate acts as a signalling molecule for neuroprotection against excitotoxicity through coordinated 
cellular pathways involving ATP production, release and activation of a P2Y/KATP cascade.
Excitotoxicity is a pathological process leading to neuronal damage and death triggered by excessive stimulation 
by glutamate of N-Methyl-D-Aspartate (NMDA) receptors1. This overstimulation of NMDA receptors causes an 
intracellular Ca2+ overload which triggers, in turn, several downstream neurotoxic cascades2. Acute brain pathol-
ogies such as stroke and spinal cord injury engage excitotoxic processes which are associated with the neuronal 
loss observed in these pathologies3,4; excitotoxicity has also been proposed as a component of certain progressive 
neurodegenerative diseases such as Alzheimer’s or Amyotrophic Lateral Sclerosis5,6. The massive activation of 
NMDA receptor being the source of excitotoxic processes, compounds interfering with NMDA receptors have 
been developed for the management of such pathological conditions and diseases. However clinical trials of 
NMDA receptors antagonists have failed due to lack of effectivity, undesired or even cytotoxic side effects7,8. In 
this context, identification of novel neuroprotective compounds that can block the deleterious biochemical cas-
cades activated downstream of NMDA receptors is therefore of interest.
Overstimulation of glutamate receptors is accompanied by a disruption of ionic homeostasis, which is restored 
through ATP-dependent ion pumps9,10. During neuronal activity, astrocyte-derived L-Lactate acts as an energy 
substrate to meet the increased energy demands of neurons11,12. L-Lactate is reported to protect mouse brain 
against excitotoxic13,14 as well ischaemic damage15,16 both after intracerebroventricular and intravenous adminis-
tration17. The mechanisms by which L-Lactate induces neuroprotection against excitotoxic and ischemic insults 
is still unknown. A natural hypothesis would be a pure metabolic mechanism by which L-Lactate rescues the 
cellular energy charge18 to maintain intracellular levels of ATP sufficient to ensure ATP-dependent ion pumps 
efficiency. Alternatively, L-Lactate-driven ATP production via the tricarboxylic acid cycle may induce neuro-
protection through the activation of specific purinergic receptors such as those on hippocampal interneurons 
where ATP activated P2Y1 receptors promote synaptic inhibition of neuronal networks19. Finally, one could also 
consider that L-Lactate directly acts as signalling molecule through membrane receptors20–22.
In the present study we have undertaken a detailed characterization of the cellular mechanisms associated 
with L-Lactate neuroprotection in a model of glutamate-induced excitotoxicity in cortical primary neuronal cul-
tures. Glutamate-induced neuronal death is monitored by quantitative phase Digital Holographic Microscopy 
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(QP-DHM), a new and non-invasive imaging technique allowing the visualization of cell structure and dynamics, 
including various biological processes in relation to transmembrane water transport, with a nanometric axial 
sensitivity23. The observation that glutamate-induced excitotoxicity triggers as an early-stage component24 a rapid 
and acute swelling of cell bodies and dendrites (i.e. an early marker of excitotoxicity) subsequent to Na+,Cl− and 
water inflows1,25, has made DHM a useful technique to detect early-stages of neuronal excitotoxic death26,27. 
Results presented here show that L-Lactate acts as a signaling molecule conferring neuroprotection against exci-
totoxic insults through a set of coordinated mechanisms based on an increase in ATP production and release and 
the subsequent activation of the P2Y receptors, mainly P2Y2, leading to an intracellular neuroprotective signaling 
pathway involving PI3 kinase and KATP channels.
Materials and Methods
Culture preparation. Experiments are conducted in accordance with the Swiss Federal Guidelines for 
Animal Experimentation and are approved by the Cantonal Veterinary Office for Animal Experimentation 
(Vaud, Switzerland). Primary cultures of cortical neurons are prepared from E17 OF1 mice embryos of either 
sex (Charles River Laboratories, L'Arbresle, France) as previously described28. Briefly, embryos are decapitated 
and brains removed and placed in a PBS-glucose solution. Cortices are removed under a dissecting micro-
scope, minced in 2 mm2 pieces, and incubated at 37 °C for 30 min in a solution containing papain 20 U/ml 
(Worthington Biochemical, Lakewood, USA), 1 mM l-cysteine, 0.5 mM EDTA, and 100 U/ml DNAase 
(Worthington Biochemical, Lakewood, USA). Papain activity is then inhibited by adding fetal calf serum and 
a single-cell suspension is obtained by gentle trituration in Neurobasal medium supplemented with B27 and 
GlutaMAX (Invitrogen, Basel, Switzerland). Cells are plated at an average density of 15000 cells/cm2 in supple-
mented Neurobasal medium on poly-ornithine coated glass coverslips (20 mm ∅ ). Neurons were maintained 
at 37 °C in a humidified atmosphere of 95% air/5% CO2 and were used after 21–35 days in vitro (DIV). These 
culture conditions typically produced 93% pure neuronal cultures, as assessed by microtubule-associated protein 
2 (MAP2) and glial fibrillary acidic protein (GFAP) co-immunostaining29.
DHM imaging. QP-DHM is an interferometric imaging technique that allows to visualize transparent spec-
imens, including living cells, by measuring the phase retardation induced by the specimens on a transmitted 
wave (for description of the basic design of the imaging system, see30). In the context of living cells recordings 
by QP-DHM, the phase retardation or the quantitative phase signal (QPS) is highly sensitive to the intracellular 
refractive index, which mainly depends on protein content31. Consequently, any transmembrane water move-
ment, modifying the intracellular refractive index through a dilution or concentration process, drastically alter 
the QPS31. Therefore, a decrease of QPS corresponds to an inflow of water while an increase of QPS indicates an 
exit of water26,31.
Quantitative phase images of perfused neuronal cell cultures are obtained as previously described31,32. Briefly, 
holograms are acquired with a DHMT 1000 (Lyncée Tech SA, PSE-EPFL; Switzerland) using a laser diode source 
(λ = 682 nm) producing a coherent beam, which is divided by a beam splitter into a reference wave and an object 
wave. The object wave diffracted by the specimen is collected by a microscope objective and interferes with the 
reference beam, according to a Mach-Zehnder configuration, to produce the hologram recorded by the CCD 
camera. Frequency of hologram acquisition is 0.2 Hz. Reconstruction of the original image from the hologram 
is numerically achieved by a computer. According to Cuche et al.33 and Colomb et al.34, the reconstruction algo-
rithm provides simultaneous amplitude and quantitative phase images of the cells (Koala software, Lyncée Tech 
SA, PSE-EPFL; Switzerland).
All cell cultures are perfused in a ACSF containing (in mM): NaCl 140, KCl 3, D-glucose 5, HEPES 10, CaCl2 
1.8, and MgCl2 0.8 (pH 7.4; room temperature). For Mg2+ free ACSF, MgCl2 is substituted by a equimolar con-
centration of CaCl2 giving rise to a final concentration of 2.6 mM for Ca2+. All drugs are dissolved and applied 
around 20 min before the beginning of optical recordings. Note that when specified L-Lactate, pyruvate and 
D-lactate are added in the ACSF medium containing 5 mM of D-Glucose. The transient application of glutamate 
(100 μ M; 2 min) are done after a minimum of 2 min of stable baseline recording of optical signal.
Offline analysis. A minimum of 20 neurons per culture are analyzed for each experiment. The optical 
recordings are analysed by using MATLAB 7.6 (Mathworks Software, Natick, USA) and all curves are fitted by 
using ORIGIN 9.5 (Microcal Software, Northampton, USA).
Cell viability assessment. For the cell viability assessment a modified configuration of the DHM T1000 
microscope was used (Lyncée Tech SA, PSE-EPFL; Switzerland) that allows measurements of both QP and fluo-
rescence signals in parallel26. Prior to experiments, coverslips were mounted on a closed chamber and cultures are 
perfused with the Mg2+ free ACSF containing (or not) L-Lactate at 10 mM. In this setup configuration, glutamate 
(1 mM; 5 min) was applied after a minimum of 2 min of stable baseline recording of QPS to induce excitotoxicity. 
Following QP-DHM imaging acquisition, cell viability is assessed with propidium iodide (PI) (Sigma-Aldrich, 
Buchs SG, Switzerland), a marker of cell death35,36. To this end, following a minimum period of 2.5 hours after 
glutamate application (time required for the occurrence of cellular death), PI (7.5 μ M) was added in the perfu-
sion medium during 15 minutes. At the end of the incubation, cells positive for PI staining, indicative of a loss 
of membrane integrity and cell death, were detected by epifluorescence microscopy. For the fluorescent system, 
excitation light is provided by a monochromator (Polychrome V, Till Photonics, Munich, Germany), delivering 
light ranging from 320 nm to 680 nm, with a power of typically 10 mW at 470 nm and a bandwidth of 15 nm. 
Employing a monochromator provides the possibility of switching rapidly the excitation wavelength without 
using any emission filter, thus avoiding any mechanical movement. The PI is excited at a single wavelength of 
λ = 490 nm and emits to 636 nm. The fluorescence light is then detected by an electron-multiplying CCD (iXon 
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DU887, Andor Technology; Belfast, UK), cooled at − 45 °C and recording 16-bit images with exposure times of 
1 second. The extraction of the two different signals is performed by employing two different dichroic mirrors, 
enabling first the separation of the line wavelength employed for digital holography, and second to enable the 
epifluorescence excitation26.
Quantitative RNA analysis. Quantitative RNA analyses for pannexins and P2Y metabotropic purinergic 
receptor family members are performed using RNA-seq as part of a whole transcriptome study aimed to charac-
terize basal gene expression levels in the neuronal cell culture model that is used in this study. Briefly, total RNA is 
isolated from DIV35 cultured neurons using Nucleospin RNA II kit (Macherey-Nagel; Oensingen, Switzerland) 
according to the manufacturer’s instructions. RNA quality is assessed on an Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, USA), and 1μ g with RNA Integrity Number above 8 were used to construct libraries using the TruSeq 
Stranded mRNA Sample Kit (Illumina; San Diego, USA) following the protocol’s instructions. First, mRNA is 
enriched using oligo dT-attached magnetic beads, fragmented, and converted into cDNA. Next, these cDNA 
fragments go through an end repair process, 3′ ends are adenylated, universal bar-coded adapters are ligated, 
and cDNA fragments are amplified by 7–8 PCR cycles to yield the final libraries. These sequencing libraries are 
evaluated and quantified using an Agilent 2100 Bioanalyzer and qPCR. Paired-end read (2 × 100 bp) multiplex 
sequencing from pooled libraries is performed on an Illumina HiSeq 2000 machine at the KAUST Bioscience 
Core Labs. Data are processed according to the method described by Trapnell et al. (2012)37. Low-quality reads 
(QC < 30) are filtered and adapter sequences trimmed using SeqClean software. TopHat is then used to align the 
reads to the mus musculus genome. Finally, Cufflinks is used to assemble the aligned reads into transcripts and to 
estimate transcripts abundance in Fragment Per Kilobase of exon per Million fragments mapped (FPKM), which 
normalizes levels of transcripts for length and total number of reads.
Statistical analysis. All data are presented as means ± SEM. Unpaired Student’s t-test or One-way ANOVA 
followed by Dunnett’s post hoc test (vs respective controls) have been used to determine statistical significance 
(p < 0.05).
Results
Glutamate triggers an irreversible decrease (ID) of phase shift specific for NMDA-dependent 
neuronal death. As previously described, early signs of neuronal death elicited by glutamate-induced exci-
totoxicity can be accurately monitored by analysing quantative phase signals (QPS) using QP-DHM26,27. In our 
highly enriched neuronal cultures29 perfused with a ACSF containing Mg2+ (0.8 mM), transient application of glu-
tamate (100 μ M; 2 min) triggers 3 types of phase responses in cells, respectively defined as biphasic (BP), revers-
ible decrease (RD) and irreversible decrease (ID) responses as revealed by DHM (Fig. 1A,C). The “BP” response 
is characterized by an initial decrease of the QPS (− 6 + /− 1.49°; ncell = 47) followed by a recovery including a 
transient increase exceeding the initial basal level (10.8 + /− 1.1°) (Fig. 1A,C). The “RD” response corresponds 
to a stronger initial decrease following by a complete recovery (− 17.6 + /− 1.25°; ncell = 121) (Fig. 1A,C). Lastly, 
the “ID” response corresponds to a pronounced and irreversible decrease of the QPS (− 47.5 + /− 3.2°; ncell = 63) 
(Fig. 1A,C). We have previously demonstrated that, in these experimental conditions, “BP” and “RD” responses 
corresponded to non-excitotoxic processes respectively associated to a mild and strong activation of NMDA 
receptors26. In these two cases, a delayed and full recovery of cell volume, hence of neuronal water and ionic 
homeostasis, was observed. In contrast, “ID” responses have been associated with excitotoxic activation of NMDA 
receptors and are characterized by an absence of cell volume recovery leading to cell death26,27. In the conditions 
used in this study (i.e. ACSF containing 0.8 mM Mg2+), the percentage of neurons displaying an “ID” response 
after a glutamate stimulation is moderate, 24 + /− 10% of cells, whereas 53 + /− 5% of neurons display an “RD” 
response and 23 + /− 5% for “BP” response (ncult = 8; ncell = 231).
We then tested the effect of the removal of Mg2+ from the extracellular solution on neuronal viability, a condi-
tion which promotes the excitotoxic activity of NMDA receptor by relieving NMDA Mg2+ block. In this specific 
condition, the percentage the “ID” responses induced by the same application protocol for glutamate (100 μ M; 
2 min) significantly increases to reach 66 + /− 6%, while “RD” and “BP” responses strongly decrease to respec-
tively 29 + /− 5% and 5 + /− 2% (ncult = 16; ncell = 461) (Fig. 1B,C). In order to confirm the correlation 
between increased “ID” pattern and increased neuronal death, QPS recordings and propidium iodide (PI) stain-
ing, a marker of cell death35,36, was performed sequentially on the same neuronal preparations. It was found that 
86% of neurons (57 out of 66 neurons) displaying an “ID” responses are also positive for PI (Fig. 1D), indicat-
ing unambiguously that “ID” response corresponds to an optical signature of the early phase of cell death pro-
cess, as previously reported using PI or trypan blue staining26,27. Of note, the amplitude of these “ID” responses 
obtained in Mg2+-free solution (− 42.4 + /− 1.28°; ncell  = 306) is similar to those obtained in Mg2+-containing 
medium (see above), strongly suggesting a shared mechanism of cell death between both conditions. Finally, 
APV (50 μ M) and MK801 (40 μ M), two specific antagonists of NMDA receptors, decrease the percentage of 
“ID” response respectively to 25 + /− 9% (ncult = 8; ncell = 223) and 6 + /− 2% (ncult = 8; ncell = 228) (Fig. 1E, 
Table 1) demonstrating that the cell death processes triggered by glutamate in Mg2+-free condition (as well as for 
Mg2+-containing condition, see above) are dependent upon the activation of NMDA receptors.
In the following experiments of this study, the “Mg2+-free condition” with an application of glutamate 
(100 μ M, 2 min) was used as a standard experimental procedure to trigger “ID” responses.
L-Lactate is neuroprotective against excitotoxicity: involvement of mitochondrial oxidative 
metabolism. In order to demonstrate its role as a neuroprotective agent, L-Lactate (10 mM) was added to 
the Mg2+-free ACSF. In these conditions, the percentage of neurons displaying a glutamate evoked “ID” response 
significantly decreases to reach 32 + /− 8% (ncult = 15; ncell = 411) (Fig. 2A–C; Table 1), while “RD” and “BP” 
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responses increase respectively to 47 + /− 5% (p < 0.05) and 21 + /− 6% (p < 0.05). Moreover, while PI label-
ling following DHM recordings indicates around 59% PI positive cells (49 out of 84 neurons; ncult = 5) in con-
trol condition, only 31% (17 out of 54 neurons; ncult = 5) are positive for PI in presence of L-Lactate, clearly 
demonstrating that L-Lactate is neuroprotective against an excitotoxic insult. Finally, this effect was shown to be 
concentration-dependent starting to be significant at a concentration of 5 mM (Fig. 2B).
We observed that another monocarboxylate, Pyruvate (10 mM), mimicks the neuroprotective action of 
L-Lactate since only 31 + /− 8% (ncult = 10; ncell = 265) of neurons present a “ID” response following glutamate 
application (Fig. 2A,C; Table 1). In contrast, substitution of L-Lactate by D-Glucose at equicaloric concentration 
(5 mM) (ncult = 10; ncell = 286), results in a slightly, but not significant, decrease of “ID” response in compari-
son with control values (52 + /− 9% vs 66 + /− 6%) (Fig. 2C; Table 1); while perfusion of D-Lactate (10 mM), 
the non-metabolized enantiomer of L-Lactate, has no effect on the occurrence of “ID” response (61 + /− 
10%; ncult = 11; ncell = 305) (Fig. 2A,C; Table 1). When considering that i) once imported into cells L-Lactate 
is converted to Pyruvate by Lactate Dehydrogenase, which is then transported into the mitochondria through 
Mitochondrial Pyruvate Carrier (MPC) and metabolically oxidized to produce ATP ii) several lines of evidence 
indicate extracellular L-Lactate as a preferred fuel for mitochondrial metabolism in neurons38,39, the above 
described results point to an important role of mitochondrial L-Lactate metabolism for neuroprotection.
In support of this view, UK5099 (1 μ M), the more potent inhibitor of the MPC40, abolishes the neuropro-
tective action of L-Lactate with a percentage of “ID” response reaching up to 61 + /− 10% (ncult = 9; ncell = 248) 
(Fig. 2C; Table 1), further indicating that L-Lactate confers neuroprotection against excitotoxic insults by an 
increase in neuronal mitochondrial energy substrate metabolism. The MCP inhibitor UK5099 is also known to 
block plasma membrane monocarboxylate transporters (MCTs) but with Ki values that are at least 2–3 orders of 
magnitude higher than those observed for MCP inhibition (micromolar vs nanomolar range)40–42, which makes 
Figure 1. Excitotoxicity elicits a specific “ID” optical response in cultured neurons as revealed by QP-
DHM. (A1,B1) Representative phase images of a neuronal culture perfused in the presence Mg2+(A1) or 
absence of Mg2+ (B1) (scale bar: 50 μ m). (A2,B2) Individual (grey line) and averaged (black line) traces of QPS 
recorded from cultured neurons respectively in (A1,B1). In the presence of Mg2+, the averaged trace obtained 
after glutamate application (100 μ M, 2 min; bar) is an “RD” response (A2) while, in the absence of Mg2+, the 
averaged trace is a “ID” response (B2). (C1,C2) Averaged traces of the 3 characteristic optical signals induced by 
glutamate application (100 μ M, 2 min; bar) in the presence of Mg2+ (C1) or absence of Mg2+ (C2). There is no 
detectable difference in terms of shape and amplitude with phase responses obtained in Mg2+ condition. (D1) 
Visualization of 2 neurons in DHM (a) and in PI staining (b), the merged image showing that the Cell n°1 is 
negative for PI and cell n°2 positive for PI (c) (scale bar: 20 μ m). (D2) Traces recorded in DHM from neurons in 
D1 indicates that the cell n°1, negative for PI, displays an “RD” response in contrast to cell n°2 positive for PI and 
displaying an “ID” response. (D3) The Bar chart shows percentage of cells positive for PI as a function of their 
phase response (ncell = 66). (E) The Bar chart shows percentage of glutamate-induced “ID” responses obtained 
in different conditions: control with Mg2+ (ncult = 8; ncell = 231), control in Mg2+ free (ncult = 16; ncell = 461), with 
APV (50 μ M) in Mg2+ free (ncult = 8; ncell = 223) and with MK801 (40 μ M) in Mg2+ free.(ncult = 8; ncell = 228). 
Results are data are presented as means ± SEM (***p < 0.005, One-way Anova/post-test “Dunnett” ).
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the concentration used in this study (1 μ M) selective for MCP inhibition. In order to determine the time window 
during which L-Lactate remains effective to neuroprotect, L-Lactate is applied at different time points (0 min, 
2 min, 5 min and 15 min) after glutamate application. L-Lactate maintains its neuroprotective property when 
applied up to 2 min after glutamate application (Fig. 2D).
Extracellular-released ATP mediates L-Lactate-induced neuroprotection. The previous set of 
data unambiguously showed that the protective effect of L-Lactate against excitotoxic injury is associated with 
mitochondrial oxidative metabolism pathway, suggesting that the neuroprotective mechanism is associated 
with the production of ATP. This observation raises the question of the mechanisms by which ATP can protect 
neurons against a glutamate excitotoxicity? Two main hypotheses are considered : i) ATP is directly used as an 
energy store to sustain cell functions (essentially to maintain ionic homeostasis by ATP-dependent pumps or 
others proteins) and/or ii) ATP acts as a signaling molecule through the activation of purinergic receptors. As 
a first approach aiming to delineate which of these hypotheses is valid, the effect of ATPγ S, a non-hydrolyzable 
form of ATP, was tested. While ATPγ S is a stable agonist of different purinergic receptors (see below) it is also 
a useful tool to exclude the involvement of energy-dependent ATP processes. Indeed, ATPγ S cannot be used 
as phosphate-bound energy donor for processes requiring ATP cleavage to ADP such as ATP-dependent ion 
Figure 2. L-Lactate is neuroprotective through mitochondrial ATP formation. (A1) (a) Representative phase 
images of neuronal culture with L-Lactate (10 mM) in the Mg2+ free ACSF (scale bar: 50 μ m). (b) Individual 
(grey line) and averaged (black line) traces of QPS recorded from cultured neurons. Note that the averaged 
trace obtained after glutamate application (100 μ M, 2 min; bar) is an “RD” response. (A2, A3) Representative 
phase images (a), individual (grey line) and averaged (black line) traces of QPS (b) recorded from cultured 
neurons treated with Pyruvate (A2) or D-Lactate (A3). Similarly to L-Lactate, the averaged trace obtained after 
glutamate application is an “RD” response with Pyruvate. In contrast, the averaged trace of QPS is an “ID” 
response with D-Lactate. (B) Concentration-response curve representing the effect of L-Lactate at different (0 
to 10 mM). Results are data are presented as means ± SEM (*p < 0.05, **p < 0.01, One-way Anova/post-test 
“Dunnett”). Numbers in brackets are the number of cells in each sampling. (C) The Bar chart shows percentage 
of glutamate-induced “ID” responses obtained in Mg2+ free ACSF containing 5 mM of D-glucose (control) 
(ncult = 16; ncell = 461), or supplied with L-Lactate (L-Lact., 10 mM) (ncult = 15; ncell = 411), Pyruvate (Pyru., 
10 mM) (ncult = 10; ncell = 265). D-Lactate (D-Lact., 10 mM) (ncult = 11; ncell = 305), D-Glucose (D-Gluc., 
5 mM) (ncult = 10; ncell = 286) or L-Lactate (10mM) + UK5099 (1μ M) (ncult = 9; ncell = 248). Results are data 
are presented as means ± SEM (*p < 0.05; **p < 0.01, One-way Anova/post-test “Dunnett”). (D) Histogram 
representing the effect of L-Lactate at different time points (20 min before; 0 min, 2 min, 5 min and 15 min after) 
of glutamate application. Note that L-Lactate remains efficient to neuroprotect even when it is applied up to 
2 min after glutamate application. Results are data are presented as means ± SEM (*p < 0.05; **p < 0.01, One-
way Anova/post-test “Dunnett”). Numbers in brackets are the number of cells in each sampling.
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pumps. In the presence of ATPγ S (10 μ M) in Mg2+ free ACSF, the averaged phase response displayed by neurons 
(ncell = 271) is a “RD”-type response (Fig. 3A), indicating that a minority of neurons underwent excitotoxic dam-
age after application of glutamate. For instance, only 33 + /− 9% of neurons of the 10 studied cultures display an 
“ID” response (Fig. 3A), in contrast to the 66 + /− 6% observed in control conditions (Fig. 3A; Table 1). These 
experiments, stress the fact that ATP is involved in this neuroprotective mechanism as a signaling molecule acting 
on purinergic receptors rather than as energy donor.
Once released into the extracellular space, ATP is degraded by ectopeptidases to the purine nucleoside aden-
osine. Both ATP and adenosine have been previously shown (in particular adenosine) to exert neuroprotective 
effects through activation of selective subtypes of purinergic receptors, notably P1 and P2 receptors for adenosine 
and ATP respectively43,44.
Since ATPγ S, cannot be cleaved to ADP (and therefore in AMP and adenosine), this L-Lactate-like effect sug-
gests that P2 receptors are a major player in the neuroprotection induced by L-Lactate. In support of this, in the 
presence in the extracellular medium of PPADS (30 μ M), a broad-spectrum blocker of P2 receptors, neuropro-
tection induced by L-Lactate against glutamate excitotoxicity is abolished (“ID” response 58 + /− 9%; ncult = 10; 
ncell = 277) (Table 1). Furthermore, incubation of adenosine (100μ M), does not reproduce the neuroprotective 
effects of L-Lactate or ATPγ S (65 + /− 9% of “ID” response; ncult = 10; ncell = 261) ruling out the involvement 
of P1 adenosine receptors in this process (Fig. 3A). Altogether, these results strongly suggest that ATP (and not 
adenosine) acts as a signaling molecule through an activation of P2 receptors for protection against a glutamate 
excitotoxicity.
To obtain further insights on the ATP-dependent activation of P2 receptors, neuronal cultures were pre-treated 
with both, L-Lactate (10 mM) and apyrase (30 U/ml), a soluble ecto-nucleotidase degrading the extracellular ATP. 
In this condition, the protective effect of L-Lactate following application of glutamate is abolished, with a percent-
age of “ID” response of 67 + /− 9% (ncult = 9; ncell = 210) (Fig. 3B) not significantly different from control values 
(p > 0.05). Finally, co-application of ATPγ S (10 μ M) together with L-Lactate and apyrase is able to re-induce 
neuroprotection with only 34 + /− 9% of “ID” responses induced by glutamate exposure (ncult = 9; ncell = 219) 
(Fig. 3B; Table 1). All these results indicate that ATP (and not its metabolites) produced by L-Lactate mitochon-
drial metabolism and released in the extracellular space induces neuroprotection by acting on P2 receptors.
A possible mechanism responsible for mediating neuronal extracellular ATP release involves pannexins, 
which are proteins expressed in neurons45 and known to play a role as ATP channels46. Quantitative expression 
of mRNA levels of pannexins isoforms in our cultures system were first determined by RNA-seq. Data shown 
in Fig. 3A indicate that mRNA for pannexin 1 and 2 are abundantly expressed in these cultured neurons. Both 
pannexins blockers probenicid (1mM) and carbenoxolone (10μ M) inhibit the neuroprotective effect of L-Lactate 
with a percentage of “ID” response (induced by glutamate) of 62 + /− 6% (ncult = 10; ncell = 287) and 57 + /− 7% 
Condition ncult ncell ≪ ID ≫ response (%)
Control 16 461 66.17 + /− 5.50
APV (50 μ M) 8 223 24.65 + /− 9.43***
MK801 (40 μ M) 8 228 5.85 + /− 2.07***
L-Lactate (10 mM) 15 411 32.08 + /− 8.44**
Pyruvate (10 mM) 10 265 30.64 + /− 8.14**
D-Lactate (10 mM) 11 305 60.76 + /− 9.52 ns
D-Glucose (5 mM) 10 286 51.90 + /− 9.16 ns
L-Lactate (10 mM) + UK5099 (1 μ M) 9 248 60.71 + /− 9.70 ns
ATPγ S (10 μ M) 10 271 32.68 + /− 8.51**
Adenosine (100 μ M) 10 261 65.33 + /− 8.97 ns
L-Lactate (10 mM) + Apyrase (30 U/ml) 9 210 67.40 + /− 8.89 ns
L-Lactate (10 mM) + Apyrase (30 U/ml) + ATPγ S (10 μ M) 9 219 33.74 + /− 8.71**
L-Lactate (10 mM) + PPADS (30 μ M) 10 277 57.94 + /− 9.12 ns
2MeSADP (10 μ M) 10 280 45.62 + /− 5.86 ns
L-Lactate (10mM) + MRS 2179 (30 μ M) 10 273 33.08 + /− 8.70*
UTPγ S (10 μ M) 10 276 34.19 + /− 9.46*
L-Lactate (10 mM) + Probenecid (1 mM) 10 287 62.46 + /− 5.68 ns
L-Lactate (10 mM) + Carbenoxolone (10 μ M) 10 285 57.15 + /− 7.45 ns
L-Lactate (10 mM) + SQ22532 (100 μ M) 10 248 34.63 + /− 7.60***
L-Lactate (10 mM) + U0126 (10 μ M) 10 273 35.69 + /− 7.91***
L-Lactate (10 mM) + LY294002 (10 μ M) 10 283 57.44 + /− 5.17 ns
UTPγ S (10 μ M) + LY294002 (10 μ M) 11 312 56.06 + /− 5.03 ns
L-Lactate (10 mM) + Glibenclamide (10 μ M) 10 283 62.39 + /− 5.47 ns
UTPγ S (10 μ M) + Glibenclamide (10 μ M) 10 296 60.30 + /− 4.41 ns
Table 1. Summary of the rate of “ID” responses induced by glutamate in different conditions. Values are 
means ± SEM. Statistics data correspond to a Dunnett’s post hoc test following a one-way ANOVA (ns: p > 0.05; 
*p < 0.05; **p < 0.01; ***p < 0.005). All presented results are obtained in Mg2+ free ACSF.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:21250 | DOI: 10.1038/srep21250
(ncult = 10; ncell = 285) respectively (Fig. 3A; Table 1), thus indicating that pannexins are the channels through 
which ATP produced by the L-Lactate/Pyruvate pathway are released.
The neuroprotective effect of L-Lactate involves a P2Y/PI3K cascade. The P2 receptor family 
comprises two subtypes, the ionotropic P2X, a family of ATP-gated cation channels, and the metabotropic P2Y, 
a family of G-protein-coupled receptors. (G-protein-coupled receptors)43,47. However, the fact that P2X recep-
tors are non-selective cation channels with high Ca2+ permeability does not argue in favour of an active role 
of these receptors in neuroprotection (i.e. activation of P2X will produce a calcium inflow additional to that of 
NMDA activation) which is consistent with observations made in several studies demonstrating that P2X recep-
tors activation is deleterious for neuronal survival48,49. These observations lead us to consider the metabotropic 
P2Y receptor family as a likely mediator of L-Lactate protective effects. Quantitative analysis of mRNA levels for 
P2Y family members indicates that mRNA for P2Y1 and P2Y2 receptors are abundantly expressed in our primary 
cultures of cortical neurons preparations (Fig. 4A). 
We observe that UTPγ S (10μ M), a specific agonist for P2Y2 receptor, significantly protects neurons against 
glutamate excitotoxicity with a percentage of “ID” responses close to 34 + /− 9% (ncult = 10; ncell = 276) (Fig. 4A 
and Table 1), suggesting that the neuroprotective activity of L-Lactate is associated with ATP-mediated activation 
of P2Y2 receptors.
Consistent with this view, 2MeSADP (10 μ M), a specific agonist of P2Y1 receptor, has no neuroprotective 
effect, since the percentage of neurons displaying an “ID” response after the application of glutamate is 46 + /− 
6% (ncult = 10; ncell = 280) (Fig. 4A; Table 1), a value lower that glutamate alone but not significantly different 
from control values (Fig. 4A). Consistent with the lack of involvement of P2Y1 receptors, the specific antagonist 
of P2Y1 receptor, MRS 2179 (30 μ M) has no inhibitory action on the neuroprotective effect of L-Lactate (33 + /− 
9%; ncult = 10; ncell = 273) (Fig. 4A and Table 1).
Figure 3. The neuroprotective effect of L-Lactate involves neuronal release of ATP through pannexins. 
(A1) With ATPγ S (10 μ M) in Mg2+ free ACSF, the averaged trace of QPS induced by glutamate (100 μ M; 2 min) 
is an “RD” response (ncult = 10; ncell = 271) in contrast to adenosine (100 μ M; ncult = 10; ncell = 261), L-Lactate 
(L-Lact., 10 mM) + Probenecid (Prob., 1 mM) (ncult = 10; ncell = 287) or L-Lactate + Carbenoxolone (Carbe., 
100 μ M) (ncult = 10; ncell = 285). (A2): Bar chart shows the percentage of glutamate-induced “ID” responses 
obtained in different conditions described in A1. Results are presented as means ± SEM (**p < 0.01, One-way 
Anova/post-test “Dunnett” ). (A3): Histogram represents the measurement of mRNA for the 3 isoforms of 
Pannexin (Pann.1, Pann.2 and Pann.3) expressed in neuronal culture. Note the absence of mRNA of Pann.3. 
(B) Two representative phase images of neuronal cultures (scale bar: 50 μ m) perfused with L-Lactate (10 mM) 
in the presence of 30U/ml of apyrase (B1a) or apyrase (30 U/ml) + ATPγ S at 10 μ M (B2a), each image being 
accompanied by the individual (grey line) and averaged (black line) traces of QPS recorded from cultured 
neurons (B1b,B2b). (B3) The averaged trace induced by glutamate application (100 μ M, 2 min; bar) in the 
presence of L-Lactate and apyrase (Apyr.) alone (ncult = 9; ncell = 210) is an “ID” response while addition of 
ATPγ S promotes an “RD” response (ncult = 9; ncell = 219). (B4) Bar chart summarizing the effects of apyrase 
(with or without APTγ S) on the occurrence of “ID” responses . Results are presented as means ± SEM 
(*p < 0.05; Unpaired t-test).
www.nature.com/scientificreports/
8Scientific RepoRts | 6:21250 | DOI: 10.1038/srep21250
P2Y2 receptors are G protein-coupled receptors activating numerous intracellular pathways47,50, including 
the phosphatidylinositol 3' –kinase (PI3K) cascade associated with the activation of different neuronal survival 
pathways51. Interestingly, in the presence of LY294002 (10 μ M), a specific blocker of PI3K, the protective effects 
of L-Lactate are prevented with a percentage of “ID” responses observed in 57 + /− 5% of neurons perfused with 
LY294002 and L-Lactate (ncult = 10; ncell = 283) (Fig. 4B; Table 1), a value significantly higher than for neurons 
treated with L-Lactate alone (Fig. 4B). This result strongly suggests that the neuroprotective effect of L-Lactate is 
linked to the activation of the PI3K cascade. In contrast, in the presence of SQ22536 (100 μ M), a blocker of the 
Adenylate Cyclase pathway or U0126 (10 μ M), a blocker of the MAP Kinase pathway, the neuroprotective effects 
of L-Lactate persist (Fig. 4B and Table 1) indicating the specific involvement of PI3K in the L-Lactate-induced 
neuroprotection.
Finally, when neuronal cultures (ncult = 11; ncell = 312) are treated with LY294002 (10μ M) and UTPγ S (10 μ M) 
in combination, 56 + /− 5% of cells display an “ID” responses after application of glutamate (Fig. 4B; Table 1), a 
percentage of “ID” response significantly higher than with UTPγ S alone (Fig. 4B), further confirming the involve-
ment of PI3K in the L-Lactate-induced P2Y2 receptors-mediated neuronal survival pathway.
PI3K-dependent neuronal survival pathway is associated to an opening of an ATP-sensitive 
potassium channel (KATP). Neuronal survival elicited by the activation of the PI3K signaling pathway is 
mostly associated with long-term inhibitory effects on the expression of pro-apoptotic factors as well as with 
promoting action on the expression of anti-apoptotic factors52. As our experimental settings rely on the detection 
Figure 4. A P2Y2/PI3K/KATP cascade mediates the neuroprotective effect of L-Lactate. (A1) Histogram 
representing the determination of mRNA for different isoforms of P2Y receptors. P2Y1 and P2Y2 are the two 
major isoforms expressed in neuronal cultures. (A2) The Bar chart shows percentage of glutamate-induced 
“ID” responses obtained in control condition (ncult = 16; ncell = 461), with L-Lactate (L-Lact., 10mM) (ncult = 15; 
ncell = 411), 2MeSADP (10μ M) (ncult = 10; ncell = 280), L-Lactate + MRS2179 (30 μ M) (ncult = 10; ncell = 273) 
and UTPγ S (10 μ M) (ncult = 10; ncell = 276). Note the significant effect of UTPγ S, the agonist of P2Y2 receptor. 
(B) Three representative phase images of neuronal cultures (scale bar: 50 μ m) perfused with L-Lactate (10mM) 
in the presence of LY294002 (10 μ M) (B1a), U0126 (10μM) (B2a), or SQ22736 (100μM) (B3a), each image being 
accompanied by the individual (grey line) and averaged (black line) traces of QPS recorded from cultured 
neurons and the histograms indicating the number of cells classified as a function of their optical responses 
(B1b,B2b,B3b). (B4) Bar chart summarizing the effects of LY294002 (ncult = 10; ncell = 283), SQ22536 (ncult = 10; 
ncell = 248) and U0126 (ncult = 10; ncell = 273) on the occurrence of “ID” responses in the presence of L-Lactate 
in Mg2+-free ACSF. Only LY294002 significantly blocked the effect of L-Lactate. (B5) Bar chart comparing the 
effect of UTPγ S (10 μ M) on the percentage of “ID” response in the presence (ncult = 11; ncell = 312) or absence 
(ncult = 10; ncell = 276) of LY294002. (C1) Bar chart shows the significant blockage of glibenclamide (Glib., 
10 μ M) on the neuroprotective effects of L-Lactate (ncult = 10; ncell = 283). This blocking effect disappears when 
glibenclamide is applied 10 min after the application of glutamate (ncult = 10; ncell = 280). (C2) Bar chart 
reports the significant blockage of glibenclamide (10 μ M) on the neuroprotective effects of UTPγ S (10μ M) 
(ncult = 10; ncell = 296). For A2, B4, and C1, results are presented as means ± SEM (*p < 0.05; **p < 0.01, One-way 
Anova/post-test “Dunnett” ). For (B5,C2), results are presented as means ± SEM (*p < 0.05; Unpaired t-test).
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of early signs of excitotoxic cell death i.e. neuronal cell swelling occurring within minutes following glutamate 
application, PI3K long-term effects on the expression of apoptotic factors do not appear to be mediators of such 
L-Lactate-mediated short-term effects. Furthermore, this notion of immediacy is reinforced by the fact that, as 
shown in Fig. 2D, the neuroprotective effect of L-Lactate is observed only when it applied with a maximum delay 
of 2 min after the onset of glutamate exposure.
In the context of rapid PI3K-dependent mediators of neuroprotection, KATP channels have emerged as poten-
tial candidates to account for the effects of L-Lactate. KATP channels are indeed involved in neuroprotection pro-
cesses53 and are regulated (i.e. activated) by the PI3K pathway54 via reduction of their sensitivity to ATP55. This 
in turn leads to a decrease in neuronal excitability, which in the context of glutamate-evoked excitotoxicity may 
be beneficial. In order to determine the importance of KATP channels in the effects of L-Lactate, glibenclamide, 
an inhibitor of KATP channel was used. Perfusion of neuronal cultures in the presence of L-Lactate (10 mM) and 
glibenclamide (10 μ M), results in a significant decrease of the neuroprotective effects of L-Lactate with a percent-
age of “ID” responses induced by glutamate of 62 + /− 5% (ncult = 10; ncell = 283) (Fig. 4C; Table 1). Similarly, the 
neuroprotective effect of P2Y2 receptor agonist UTPγ S (10 μ M) is lost in the presence of glibenclamide (10 μ M) 
since the percentage of “ID” responses reaches up 60 + /− 4% (ncult = 10; ncell = 296) (Fig. 4C). Of note, gliben-
clamide is no more effective in blocking L-Lactate effect when added 10min after glutamate application (ncult = 
10; ncell = 280) (Fig. 4C). These results highlight the importance of the P2Y2/PI3K pathway and the activation 
of KATP channel in the L-Lactate-induced neuroprotective actions. Altogether these results demonstrate that the 
neuroprotective effect of L-Lactate against the excitotoxic action of glutamate is linked to the final activation of 
the KATP channel through the mobilization of the P2Y2/PI3K pathway.
Discussion
Initial phases of cellular death triggered by an excessive glutamate stimulation are characterized by a massive 
ionic and water inflows56. Taking advantage of the QP-DHM technique to monitor transmembrane water fluxes 
associated with early stages of neuronal death processes26,27, we demonstrate that L-Lactate acts as a signaling 
molecule conferring neuroprotection against excitotoxic insults through well-coordinated mechanisms based 
on an increase neuronal energy substrates availability, a release of ATP and an intracellular signaling PI3 kinase 
pathway triggered by purinergic receptors, likely P2Y2, followed by the activation of the KATP channels as sum-
marized in Fig. 5.
Until now, the few in vitro studies exploring the neuroprotective properties of L-Lactate have suggested a 
mechanism of action involving the maintenance of the cellular energy charge18. Indeed, excitotoxicity is clas-
sically associated with inhibition of oxidative phosphorylation resulting in a loss of ATP to fuel ion pumps to 
re-establish the ionic homeostasis9,10. In agreement with that, the involvement of the L-Lactate/Pyruvate pathway 
and the mitochondrial activity was also observed in this study. Since L-Lactate is converted to Pyruvate by Lactate 
Dehydrogenase, it would seem logical that both, L-Lactate and Pyruvate are equivalent to produce ATP through 
the oxidative pathway (Fig. 5). In contrast, glucose does not evoke a significant neuroprotective effect consistent 
with the view that L-Lactate is a preferred fuel for mitochondrial metabolism in neurons38,39 and also in view of 
the fact that glutamate inhibits glucose transport in neurons57. Such view is supported by in vivo studies demon-
strating the involvement of a L-Lactate/Pyruvate pathway for neuroprotection13,58,59. In contrast to these observa-
tions and to our present results, a recent study evidenced a neuroprotective role of D-lactate and L-lactate through 
a common mechanism involving energy production and activation of HCA1, a lactate receptor, suggesting that 
different D/L-lactate-induced neuroprotective pathways may operate in vivo60.
Another important data reported in the present study indicate the existence of an additional mechanism 
independent of an energetic role of L-Lactate linked to the formation of ATP since ATPγ S, a non-hydrolysable 
ATP, mimicked effect of L-Lactate (and of Pyruvate). Indeed data indicate that ATP produced by the L-Lactate/
Pyruvate neuroenergetic pathway acts as signaling molecule following its release through the ATP channels pan-
nexins, a mode of release in agreement with the biophysical properties of the pannexins known to be a mech-
anosensitive conduits for ATP sensitive to swelling46,61. Interestingly, ATP released by neurons acts in autocrine/
paracrine manner triggering an apyrase-sensitive purinergic signaling (Fig. 5). Such ATP-signaling cascade has 
been observed occurring not only in neurons62 but also in astrocytes63, these glial cells expressing both pannex-
ins and purinergic receptors64,65. This could suggest that the very few contaminating astrocytes in our neuronal 
cultures model may also participate in the activation of such a signaling cascade. Nevertheless, while we cannot 
fully exclude a participation of astrocytes the biological effects of L-Lactate described here, the high enrichment 
of neurons in our culture model, 93%29, and therefore the low level of contaminating astrocytes, less than 7% of 
glial cells, makes it unlikely.
Concerning the nature of ATP-activated receptors, it is known that both, P1 adenosine and P2 purinergic 
receptors are involved in neuroprotection66. Thus, a neuroprotective role of adenosine through the activation 
of specific P1 receptors (i.e. A1) has been demonstrated, which was shown to be dependent on a decrease in 
extracellular glutamate release associated to an inhibition of excitatory synaptic transmission67–69. However, the 
neuroprotective effect of ATPγ S along with the use of specific agonists and antagonists clearly indicates that the 
receptors involved in the effects described here are not adenosine receptors. The blockade of L-Lactate neuro-
protection by apyrase confirms the pivotal role played by ATP originating from the L-Lactate/Pyruvate path-
way through activation of P2 purinergic receptors, mostly the metabotropic P2Y family since ionotropic P2X 
receptors are non-selective cation channels with high Ca2+ permeability, an argument which is not in favour 
of an active role of these receptors in neuroprotection. It has been shown that ATP can exert neuroprotective 
actions through activation of neuronal purinergic P2Y2 receptors in a serum starvation-induced model51. P2Y 
subunits are known to potentially form homomeric or heteromeric assemblies with distinct types of GPCRs 
through direct association, providing complex non-canonical pharmacological responses to agonists/antagonists 
and downstream signaling pathways70, a fact that may preclude the identification of the role played by a given P2 
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receptor subtype in a physio(patho)logical process. Nevertheless, results obtained in this study and in particu-
lar the observation that UTPγ S, a specific activator of P2Y2 receptor mimics the protective effects of L-Lactate 
points to a major role played by this receptor subtype in L-Lactate-mediated neuroprotection against excitotox-
icity. An interesting point concerns a putative dual role played by ATP in neurotoxic and neuroprotective pro-
cesses. Indeed, excessive release of ATP is known to promote neuronal death, in particular through the activation 
of a P2X7-pannexins complex71. Purinergic receptors display a very broad range of ATP sensitivities, ranging 
from nanomolar in the case of P2Y receptors up to hundred micromolar for P2X receptors72, activation of these 
receptors may therefore be associated with neuroprotective or neurotoxic effects respectively. This implies that 
depending on the ATP concentration reached in the extracellular medium different P2 receptors subtypes may be 
activated, hence either neuroprotective or neurotoxic cascades.
The P2Y2/PI3K pathway has been described as an important survival pathway through an inhibition of apop-
totic processes51. Here we show, that the P2Y2/PI3K pathway can also promote neuronal survival through a rapid 
and non-genomic action involving the activation of the KATP channel (Fig. 5). Such interactions between PI3K 
pathway and KATP channels have been described in hypothalamic proopiomelanocortin neurons participating in 
the inhibition of food intake55. In particular, it was demonstrated that PI3K pathway enhances PIP3 signaling, 
resulting in the activation of KATP channels via reduction of the channel sensitivity to ATP. This type of intracellu-
lar mechanism resulting in the activation of KATP channels and prevention of depolarization, may also be related 
to neuroprotection. Indeed, while ATP production is necessary to maintain the activity of ATP-dependent ion 
pumps to restore the ionic balance disrupted by an overstimulation of glutamate receptors, this increase in ATP 
levels can also lead to a closure of KATP channels, with final result being a neuronal depolarization and, as a con-
sequence, the maintenance of the neuronal death processes (Fig. 5). The PI3K-dependent process that we have 
revealed would therefore play a protective role by activating KATP channels despite an increase in intracellular 
ATP levels produced by L-Lactate/Pyruvate mitochondrial oxidation. The involvement of PI3K pathway appears 
to be critical for neuronal survival because ATPγ S (or UTPγ S) alone are sufficient to provide neuroprotection.
Other studies have shown that L-Lactate (and Pyruvate) exert their protecting effect by decreasing the delayed 
accumulation of extracellular glutamate known to be associated with excitatory insults induced by long-term 
exposure to NMDA18. Our results suggest that the activation of KATP channels by the P2Y2/PI3K pathway can 
be the underlying mechanism responsible for the decrease in the delayed glutamate accumulation described 
above by reducing the neuronal network excitability, hence decreasing global glutamate release. Interestingly, we 
have previously demonstrated that the shape and amplitude of optical responses triggered by glutamate applica-
tion reflected the excitability of the neuronal network, particularly the level of NMDA activity26. In this general 
context, it would be of interest to determine whether differences in terms of levels of expression and activation 
of the key elements involved in the neuroprotective cascade induced by L-Lactate as described in this study 
could explain (or be involved in) the differential physiological response of neurons to L-Lactate (i.e. “RD” vs “ID” 
neurons).
In addition to its role in energy metabolism, there is growing evidence that L-Lactate can act as signaling 
molecule12,73,74 in particular during physiological processes like Long-Term Memory formation75. There is an 
Figure 5. Schematic representation of the mechanisms involved in the neuroprotective effect of L-Lactate 
against excitotoxicity. Over stimulation of NMDA receptors by glutamate triggers a strong inflow of Ca2+; this 
overload of Ca2+ leading to excitotoxic cell death processes (1). L-Lactate is transported into the cell (2) and 
converted to Pyruvate by Lactate Dehydrogenase (LDH) (3). Pyruvate is transported into mitochondria through 
the Mitochondrial Pyruvate Carrier (MPC) to produce ATP (4). ATP is then released through pannexins and 
acts on the metabotropic purinergic receptor P2Y, likely P2Y2, in a autocrine/paracine manner (5). Stimulation 
of purinergic receptors activates the PI3K pathway (6) which, in turn, elicits the opening of KATP channels, 
hence leading to hyperpolarization of neurons (7), the consequence being a decrease in neuronal excitability 
leading to neuroprotection.
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apparent paradox in the effects of L-Lactate , as two contrasting effects appear to exist: a stimulation of plasticity 
and learning mediated by potentiation of the NMDA receptor activity73 which coexists with a neuroprotective 
effect of L-Lactate against excessive NMDA receptor activity (excitotoxicity). As shown here, it is actually con-
ceivable that the coexistence of these two effects represents a coordinated and well balanced set of mechanisms 
that allows to potentiate NMDA receptor activity while mitigating its potential pernicious effects. The tempo-
ral deployment of these two effects would be consistent with this view, as the neuroprotective effect is rapidly 
expressed, within 2 minutes (this study), while the effect on plasticity is delayed in time between 30 minutes and 
4 hours depending on the genes induced73.
Our study provides new evidences that L-Lactate can also act as a signaling molecule in pathological contexts 
such as excitotoxic processes. Considering that astrocytes are the main producers of L-Lactate in brain, our obser-
vations point to astrocytes as pivotal cellular elements for neuronal protection against excitotoxicity. For instance, 
glutamate released during neuronal activity stimulates glucose uptake and L-Lactate production and release from 
astrocytes11. Boosting this process, also known as aerobic glycolysis or Warburg effect12 indeed results in neuro-
protection76. Therefore, during an excitotoxic situation, the pathological release of glutamate from neurons would 
strongly activate L-Lactate production and the release from astrocytes which, in turn, would provide neuropro-
tection by opening KATP channels, through the P2Y2/PI3K pathway.
In summary, the present results indicate that L-Lactate can be an attractive candidate as a neuroprotective 
compound, providing the opportunity to develop neuroprotective strategies aimed at increasing the production 
of L-Lactate by astrocytes.
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